Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 3/20 | 0.63 |
| ▸ | PTPRCAP | Q14761 | 2/20 | 0.63 |
| ▸ | RARB | P10826 | 6/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | RARA | P10276 | 5/20 | 0.47 |
| ▸ | RARG | P13631 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5828122 | 0.89 | PTPN11 (0.77) | PTPN11PTPRCAPRARBHDAC11HDAC2 | |
| SCHEMBL5828120 | 0.89 | PTPN11 (0.77) | PTPN11PTPRCAPRARBHDAC11HDAC2 | |
| SCHEMBL5827656 | 0.85 | PTPN11 (0.56) | PTPN11PTPRCAPRARBHDAC11HDAC2 | |
| SCHEMBL5828666 | 0.85 | PTPN11 (0.49) | PTPN11PTPRCAPRARBHDAC11HDAC2 | |
| SCHEMBL5828517 | 0.84 | PTPN11 (0.53) | PTPN11PTPRCAPRARBHDAC11HDAC2 | |
| SCHEMBL5828556 | 0.84 | HDAC11 (0.57) | PTPN11PTPRCAPRARBHDAC11HDAC2 | |
| SCHEMBL5827560 | 0.82 | PTPN11 (0.74) | PTPN11PTPRCAPRARBHDAC11HDAC2 | |
| SCHEMBL5827559 | 0.82 | PTPN11 (0.74) | PTPN11PTPRCAPRARBHDAC11HDAC2 | |
| SCHEMBL5828564 | 0.81 | PTPN11 (0.85) | PTPN11PTPRCAPRARBHDAC11HDAC2 | |
| SCHEMBL5828563 | 0.81 | PTPN11 (0.85) | PTPN11PTPRCAPRARBHDAC11HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | claimed |
| US-7153875-B2 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE SAN DIEGO (US) | 2006-12-26 | — | — | US | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | PTPN11 1985/4885PTPRCAP 3488/4885RARB 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.